Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
Agarwal, Vijay; Lind, Michael J.; Cawkwell, Lynn
Professor Michael Lind M.J.Lind@hull.ac.uk
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies
The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients.
Agarwal, V., Lind, M. J., & Cawkwell, L. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), 533-542. https://doi.org/10.1016/j.ctrv.2010.11.004
|Journal Article Type||Article|
|Acceptance Date||Nov 19, 2010|
|Online Publication Date||Dec 22, 2010|
|Journal||Cancer treatment reviews|
|Peer Reviewed||Peer Reviewed|
|Keywords||Oncology; Radiology Nuclear Medicine and imaging; General Medicine|
You might also like
The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma